KOSDAQ - Delayed Quote KRW

OliX Pharmaceuticals, Inc (226950.KQ)

56,600.00

+2,300.00

+(4.24%)

At close: 3:30:22 PM GMT+9

OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications

SEONGNAM, South Korea, February 10, 2025--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.

Business Wire 3 months ago

226950.KQ
+4.24%

Performance Overview

Return	226950.KQ	KOSPI Composite Index (^KS11)
YTD	+193.87%	+12.48%
1-Year	+298.59%	+2.37%
3-Year	+134.85%	+1.50%